Quest Diagnostics (NYSE:DGX) Cut to Neutral at Citigroup
Citigroup cut shares of Quest Diagnostics (NYSE:DGX – Free Report) from a buy rating to a neutral rating in a report published on Tuesday, MarketBeat reports. They currently have $185.00 target price on the medical research company’s stock. Several other brokerages have also recently issued reports on DGX. UBS Group increased their price objective on […]
Citigroup cut shares of Quest Diagnostics (NYSE:DGX – Free Report) from a buy rating to a neutral rating in a report published on Tuesday, MarketBeat reports. They currently have $185.00 target price on the medical research company’s stock. Several other brokerages have also recently issued reports on DGX. UBS Group increased their price objective on […]
